SDC1 and cancer: In previous studies, in a few cancers, such as head/neck, lung, colorectal, gastric, and renal cancers, CD138 expression was found to be reduced, while multiple cancers including breast, gallbladder, pancreatic, ovarian, endometrial, urinary, bladder, and prostate cancer showed its overexpression.